Contineum Therapeutics, Inc.
CTNMHealthcare|Biotechnology|US
$9.52
+0.71 (+8.06%)
DCF Value
$2.40
Tangible Book / Share
$6.39
Cash / Share
$6.37
Financials
Financial Snapshot
Market Cap
$336.6M
Enterprise Value
$267.6M
Revenue (TTM)
$0.00
Net Income (TTM)
-$63.5M
Cash & Investments
$244.5M
Net Cash
$238.2M
Free Cash Flow (TTM)
-$52.2M
Operating CF (TTM)
-$51.9M
Debt/Equity
0.03
Cash Runway & Burn Rate
Cash on Hand
$244.5M
Quarterly Burn
$13.0M
Monthly Burn
$4.3M
Est. Runway
~18.9 quarters
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $69.0M | $47.2M | $125.2M | $204.8M | $262.9M | $244.5M | |
| Operating Cash Flow | -$26.3M | -$20.1M | $19.3M | -$32.8M | -$55.3M | -$51.9M | |
| Free Cash Flow | -$26.4M | -$20.2M | $18.9M | -$33.4M | -$55.5M | -$52.2M | |
| Capital Expenditure | -$168.0K | -$118.0K | -$414.0K | -$514.0K | -$231.0K | -$360.0K | |
| Financing Cash Flow | $79.8M | -$1.2M | $56.2M | $109.0M | $112.7M | $115.4M |
R&D Spending
R&D (TTM)
$53.1M
R&D Intensity
—
R&D Growth vs Prior
+3.0%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $50.0M | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $22.4M | $16.9M | $27.6M | $38.2M | $51.5M | $53.1M | |
| R&D % of Revenue | — | — | 55.2% | — | — | — | |
| SG&A | $6.3M | $5.8M | $6.3M | $12.5M | $16.5M | $19.3M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $50.0M | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $258.0K | $0.00 | $81.0K | |
| Gross Profit | $0.00 | $0.00 | $50.0M | -$258.0K | $0.00 | -$81.0K | |
| R&D | $22.4M | $16.9M | $27.6M | $38.2M | $51.5M | $53.1M | |
| SG&A | $6.3M | $5.8M | $6.3M | $12.5M | $16.5M | $19.3M | |
| Operating Income | -$28.6M | -$22.7M | -$16.1M | -$50.9M | -$68.1M | -$72.4M | |
| Interest Expense | $332.0K | $388.0K | $208.0K | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$29.0M | -$24.3M | $23.2M | -$42.3M | -$60.0M | -$63.5M | |
| Net Income | -$29.0M | -$24.3M | $22.7M | -$42.3M | -$60.0M | -$63.5M | |
| EPS (Diluted) | -1.15 | -0.97 | 0.13 | -1.63 | -2.17 | -1.77 | |
| EBITDA | -$28.3M | -$23.5M | $23.6M | -$42.0M | -$67.7M | -$72.1M | |
| Shares Out. (M) | 25.13 | 25.13 | 25.13 | 25.85 | 27.70 | 38.39 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.6M | $5.6M | $15.5M | $21.9M | $75.6M | $75.2M | |
| Short-Term Investments | $64.4M | $41.7M | $109.7M | $182.8M | $187.3M | $169.3M | |
| Total Current Assets | $69.8M | $48.4M | $127.7M | $206.4M | $267.9M | $249.7M | |
| Total Assets | $70.5M | $50.6M | $130.4M | $212.8M | $276.6M | $257.0M | |
| Total Current Liabilities | $3.7M | $7.5M | $5.5M | $10.0M | $9.7M | $8.0M | |
| Long-Term Debt | $3.7M | $0.00 | $192.6M | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $8.9M | $11.4M | $198.3M | $14.8M | $15.7M | $11.6M | |
| Stockholders' Equity | $61.6M | $39.3M | -$67.9M | $198.1M | $261.0M | $245.4M | |
| Retained Earnings | -$73.6M | -$97.9M | -$75.1M | -$117.4M | -$177.4M | -$225.7M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$26.3M | -$20.1M | $19.3M | -$32.8M | -$55.3M | -$51.9M | |
| Capital Expenditure | -$168.0K | -$118.0K | -$414.0K | -$514.0K | -$231.0K | -$360.0K | |
| Free Cash Flow | -$26.4M | -$20.2M | $18.9M | -$33.4M | -$55.5M | -$52.2M | |
| Investing Cash Flow | -$65.0M | $22.3M | -$65.6M | -$69.7M | -$3.7M | -$31.0M | |
| Financing Cash Flow | $79.8M | -$1.2M | $56.2M | $109.0M | $112.7M | $115.4M | |
| Issuance of Stock | $113.0K | $15.0K | $159.0K | $109.0M | $112.9M | $115.4M | |
| Repurchase of Stock | $0.00 | -$4.0K | -$28.0K | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | -$1.3M | -$3.8M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.7M | $1.9M | $2.2M | $6.8M | $10.0M | $15.0M | |
| Net Change in Cash | -$11.4M | $939.0K | $10.0M | $6.4M | $53.7M | $32.6M |
Dilution Tracker
Shares Outstanding
35M
5-Year Share Growth
+10.2%
Stock Issuance (TTM)
$115.4M
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 25.13 | 25.13 | 25.13 | 25.85 | 27.70 | 38.39 | |
| Change vs Prior % | — | 0.0% | 0.0% | 2.9% | 7.1% | 38.6% | |
| Stock Issuance | $113.0K | $15.0K | $159.0K | $109.0M | $112.9M | $115.4M | |
| Stock Repurchase | $0.00 | -$4.0K | -$28.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.7M | $1.9M | $2.2M | $6.8M | $10.0M | $15.0M |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | 100.0% | — | — | — | |
| Operating Margin % | — | — | -32.2% | — | — | — | |
| Net Margin % | — | — | 45.4% | — | — | — | |
| EBITDA Margin % | — | — | 47.1% | — | — | — | |
| FCF Margin % | — | — | 37.9% | — | — | — | |
| ROE % | -47.1% | -61.8% | -33.4% | -21.3% | -23.0% | -25.5% | |
| ROA % | -41.1% | -47.9% | 17.4% | -19.9% | -21.7% | -24.7% | |
| ROIC % | -42.1% | -47.2% | -12.6% | -24.9% | -25.3% | -28.8% | |
| R&D / Revenue % | — | — | 55.2% | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -100.5% | 100.0% | |
| Operating Income | 0.0% | 20.7% | 29.2% | -216.6% | -33.7% | |
| Net Income | 0.0% | 16.4% | 193.7% | -286.0% | -41.9% | |
| EPS (Diluted) | 0.0% | 15.7% | 113.4% | -1353.8% | -33.1% | |
| Operating Cash Flow | 0.0% | 23.4% | 196.2% | -269.8% | -68.4% | |
| Free Cash Flow | 0.0% | 23.4% | 193.6% | -276.2% | -66.5% | |
| R&D Expense | 0.0% | -24.4% | 63.4% | 38.3% | 35.0% | |
| SG&A Expense | 0.0% | -7.3% | 8.5% | 97.3% | 32.6% | |
| Total Assets | 0.0% | -28.2% | 157.5% | 63.2% | 30.0% | |
| Book Value / Share | 0.0% | -36.2% | -273.0% | 383.4% | 23.0% | |
| Debt | 0.0% | 19.1% | 3203.0% | -96.8% | 31.8% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 2.9% | 7.1% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.49
10Y Low / Med / High1.21 / 6.28 / 9.86
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$2.40
Tangible Book / Share
$6.39
Net Current Assets / Share
$6.74
Graham Net-Net
$6.07
Cash / Share
$6.37
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | -13.39 | -15.88 | 118.46 | -8.99 | -5.27 | -5.38 | |
| P/S Ratio | 0.00 | 0.00 | 7.74 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 6.28 | 9.86 | -5.70 | 1.91 | 1.21 | 1.49 | |
| EV/EBITDA | -13.67 | -16.46 | 23.95 | -8.64 | -3.68 | -3.71 | |
| EV/Revenue | 0.00 | 0.00 | 11.29 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
16.42
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $4.3M | $2.2M | $3.4M |
| Net Income | -$49.4M | -$59.6M | -$55.6M |
| EPS | $-1.78 | $-2.10 | $-2.01 |
| # Analysts (EPS) | 5 | 5 | 2 |